ARCHIVES

Risk-Benefit Analysis Advised Prior To Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 33 No. 8 | August 27, 2010

Download PDF Visit The Full Archive

Related Articles

VIB CIDAC contract Extended, No Gaps In CANCERGRAMS

June 15, 1984

Upton Promises “Minimal Disruption” As Result of Changes; Centers Program Probably To Move

January 20, 1978

FEBT, For Pain Control, Shows Positive Results In Phase III

May 26, 2006

Clinton’s FY97 Budget Sees $12.4 Billion For NIH, $2.28B For NCI

March 22, 1996

Fountain Displays Some Statesmanship

July 8, 1977

Medicare coverage and quality of care top ASCO’s list of policy priorities for 2004.

February 27, 2004